EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clonal Haematopoiesis is Associated with Major Adverse Cardiovascular Events in Patients with Hypertrophic Cardiomyopathy

Fernando L Scolari, Darshan Brahmbhatt, Sagi Abelson, Deacon Lee, Raymond H Kim, Ali Pedarzadeh, Ali Sakhnini, Arnon Adler, Raymond H Chan, John E Dick, Harry Rakowski, Filio Billia

European Journal of Heart Failure · 01.10.2024 · 26 (10) · 2193-2202

DOI: 10.1002/ejhf.3408 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 01.08.2024. Verfasst von Fernando L Scolari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Clonal Hematopoiesis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The heterogeneous phenotype of hypertrophic cardiomyopathy (HCM) is still not fully understood. Clonal haematopoiesis (CH) is emerging as a cardiovascular risk factor potentially associated with adverse clinical events. The prevalence, phenotype and outcomes related to CH in HCM patients were evaluated. Methods and results Patients with HCM and available biospecimens from the Peter Munk Cardiac Centre Cardiovascular Biobank were subjected to targeted sequencing for 35 myeloid genes associated with CH. CH prevalence, clinical characteristics, morphological phenotypes assessed by echocardiogram and cardiac magnetic resonance and outcomes were assessed. All patients were evaluated for a 71-plex cytokines/chemokines, troponin I and B-type natriuretic peptide analysis. Major adverse cardiovascular events (MACE) were defined as appropriate implantable cardioverter-defibrillator shock, stroke, cardiac arrest, orthotopic heart transplant and death. Among the 799 patients, CH was found in 183 (22.9%) HCM patients with sarcomeric germline mutations. HCM patients with CH were more symptomatic and with a higher burden of fibrosis than those without CH. CH was associated with MACE in those HCM patients with sarcomeric germline mutations (adjusted hazard ratio [HR] 6.89, 95% confidence interval [CI] 1.78–26.6; p = 0.005), with the highest risk among those that had DNMT3A, TET2 and ASXL1 mutations (adjusted HR 5.76, 95% CI 1.51–21.94; p = 0.010). Several cytokines (IL-1ra, IL-6, IL-17F, TGFα, CCL21, CCL1, CCL8, and CCL17), and troponin I were upregulated in gene-positive HCM patients with CH.

Conclusions

These results indicate that CH in patients with HCM is associated with worse clinical outcomes. In the absence of CH, gene-positive patients with HCM have lower rates of MACE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicClonal HematopoiesisHumansMaleFemaleMiddle AgedDNA Methyltransferase 3ARepressor ProteinsProto-Oncogene ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA-Binding ProteinsTroponin IAgedEchocardiographyPhenotypeCytokinesNatriuretic Peptide, BrainMutationAdultRisk FactorsHeart ArrestDioxygenases

Stichwörter der Autor:innen

Cardiac magnetic resonance imagingClonal haematopoiesisFibrosisHypertrophic cardiomyopathyInflammation

Substanzen

DNMT3A protein, humanDNA Methyltransferase 3ATET2 protein, humanASXL1 protein, humanRepressor ProteinsProto-Oncogene ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA-Binding ProteinsTroponin ICytokines

Autor:innen und Institutionen

  • Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada.
  • Ted Rogers Centre for Heart Research, Toronto, ON, Canada.
  • Toronto General Hospital Research Institute, Toronto, ON, Canada.
  • Mount Sinai Hospital, Toronto, ON, Canada.
  • Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

Zitieren

APA

Scolari, F. L., Brahmbhatt, D., Abelson, S., Lee, D., Kim, R. H., Pedarzadeh, A., Sakhnini, A., Adler, A., Chan, R. H., Dick, J. E., Rakowski, H., & Billia, F. (2024). Clonal Haematopoiesis is Associated with Major Adverse Cardiovascular Events in Patients with Hypertrophic Cardiomyopathy. European Journal of Heart Failure, 26(10), 2193-2202. https://doi.org/10.1002/ejhf.3408

Vancouver

Scolari FL, Brahmbhatt D, Abelson S, Lee D, Kim RH, Pedarzadeh A, et al. Clonal Haematopoiesis is Associated with Major Adverse Cardiovascular Events in Patients with Hypertrophic Cardiomyopathy. European Journal of Heart Failure. 2024;26(10):2193-2202. doi:10.1002/ejhf.3408

BibTeX
@article{Scolari2024,
  author = {Scolari, Fernando L and Brahmbhatt, Darshan and Abelson, Sagi and Lee, Deacon and Kim, Raymond H and Pedarzadeh, Ali and Sakhnini, Ali and Adler, Arnon and Chan, Raymond H and Dick, John E and Rakowski, Harry and Billia, Filio},
  title = {Clonal Haematopoiesis is Associated with Major Adverse Cardiovascular Events in Patients with Hypertrophic Cardiomyopathy},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {10},
  pages = {2193--2202},
  doi = {10.1002/ejhf.3408}
}
Kostenlos starten →